Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085
administered as a single agent in patients with relapsed or refractory multiple myeloma
(RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion
Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at
the RP2D in patients with RRMM
To characterize the safety profile of SAR442085
To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a
To evaluate the potential immunogenicity of SAR442085
To assess preliminary evidence of antitumor activity in the Dose Escalation Part A
Patient will continue to receive study medication until disease progression, unacceptable
toxicity, withdrawal of informed consent, or other reason why investigator considers it
appropriate to discontinue study medication. Once permanently discontinued, study medication
cannot be restarted at later timepoint.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.